351 related articles for article (PubMed ID: 11118469)
41. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
42. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
43. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
[TBL] [Abstract][Full Text] [Related]
44. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
45. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Tytgat GA
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
[TBL] [Abstract][Full Text] [Related]
46. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
Uttenreuther-Fischer MM; Huang CS; Yu AL
Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
[TBL] [Abstract][Full Text] [Related]
48. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
[TBL] [Abstract][Full Text] [Related]
49. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
[TBL] [Abstract][Full Text] [Related]
50. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
[TBL] [Abstract][Full Text] [Related]
52. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
53. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.
Cheung IY; Hsu K; Cheung NK
J Clin Oncol; 2012 Feb; 30(4):426-32. PubMed ID: 22203761
[TBL] [Abstract][Full Text] [Related]
54. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
Navid F; Sondel PM; Barfield R; Shulkin BL; Kaufman RA; Allay JA; Gan J; Hutson P; Seo S; Kim K; Goldberg J; Hank JA; Billups CA; Wu J; Furman WL; McGregor LM; Otto M; Gillies SD; Handgretinger R; Santana VM
J Clin Oncol; 2014 May; 32(14):1445-52. PubMed ID: 24711551
[TBL] [Abstract][Full Text] [Related]
55. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
Kushner BH; Cheung NK
Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466
[TBL] [Abstract][Full Text] [Related]
56. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
Desai AV; Fox E; Smith LM; Lim AP; Maris JM; Balis FM
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1047-55. PubMed ID: 25212536
[TBL] [Abstract][Full Text] [Related]
58. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
[TBL] [Abstract][Full Text] [Related]
59. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
[TBL] [Abstract][Full Text] [Related]
60. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
